Episodios

  • Biohacking Industry Crisis: Credibility Collapse and the Future of Longevity Science

    Biohacking Industry Crisis: Credibility Collapse and the Future of Longevity Science
    Apr 28 2026
    In the past 48 hours, the biohacking industry is grappling with a severe credibility crisis sparked by revelations of Peter Attia's ties to Jeffrey Epstein, as detailed in a YouTube video by James Welsh on April 26, 2026, which has amassed over 5,600 views.[1] Attia, once a pillar of the longevity movement through his podcast The Drive, book Outlive, and advocacy for healthspan, fasting, VO2 max, and supplements, resigned from CBS on February 23, 2026, amid scandal, intensifying doubts about the sectors blend of science and hype.[1] No new product launches, deals, partnerships, or regulatory changes have surfaced in this period, signaling a stall in momentum.[1] Verified statistics from the past week remain absent for market movements, price shifts, supply chain issues, or consumer behavior changes, though online scrutiny of influencers has surged.[1] Chinese peptide imports, a biohacking staple, nearly doubled to about 328 million dollars in the first nine months of an unspecified recent year, hinting at supply growth but raising quality concerns.[4] This echoes 2023 controversies, like Attias Oura Ring lawsuit over stock options and study influence, underscoring recurring corruption fears over innovation.[1] Biotech giants such as Calico Life Sciences and Unity Biotechnology, funded by billions from Peter Thiel and Jeff Bezos since the 2010s, face eroding trust in unproven therapies like plasma transfusions and epigenetic tests.[1] Industry leaders have stayed silent on responses, potentially forcing a pivot from hype to evidence-based practices.[1] A separate 20-week sleep study tied to Dave Aspreys Beyond Biohacking Conference challenges performance assumptions, while Evolutamente promotes light-based health gains among biohackers.[3][5] Overall, the sector confronts trust erosion without fresh catalysts, contrasting any prior innovation buzz with current introspection.(298 words) For great deals today, check out https://amzn.to/44ci4hQ
    Más Menos
    2 m
  • Biohacking's Credibility Crisis: What Longevity Industry Faces Now

    Biohacking's Credibility Crisis: What Longevity Industry Faces Now
    Apr 27 2026
    2 m
  • Biohacking Market Surges to 67 Billion by 2035: Take Solutions Leads India Expansion

    Biohacking Market Surges to 67 Billion by 2035: Take Solutions Leads India Expansion
    Apr 24 2026
    2 m
  • Biohacking in 2026: AI Innovation Amid Drug Pricing Pressure and Chinese Competition

    Biohacking in 2026: AI Innovation Amid Drug Pricing Pressure and Chinese Competition
    Apr 23 2026
    2 m
  • Biohacking 2026: Energy Optimization, Nonna-Maxxing, and Mitochondrial Support Trends

    Biohacking 2026: Energy Optimization, Nonna-Maxxing, and Mitochondrial Support Trends
    Apr 22 2026
    In the past 48 hours, the biohacking industry shows steady momentum driven by 2026 consumer trends toward energy optimization and natural longevity hacks, with no major market disruptions or regulatory shifts reported. Thorne Research leads with its Magnesium Bisglycinate Powder 2026 Lemon-Lime Formula, positioning itself as a global staple for biohackers seeking enhanced recovery and sleep, amid rising demand in Europe like Belgium.[4] Mitolyn gains traction as users tackle multitasking fatigue from longer work hours, reflecting broader shifts where 2026 lifestyles prioritize mitochondrial support and mental clarity.[5] Emerging trends highlight "nonna-maxxing," a TikTok viral phenomenon embracing Italian grandmother routines—cooking from scratch, family meals, walks, and less screen time—for longevity, inspired by Blue Zones like Sardinia where centenarians thrive on whole foods and social bonds.[7] This contrasts with high-tech protocols, signaling a consumer pivot to simple, ancestral habits over gadgets. Product buzz includes Synaptigen's neuroscience framework, noting 4 percent of users experience mild gut bloating in the first 48 to 72 hours from potent probiotics, and NeuroPrime's vasodilation effects causing temporary headaches in early users.[1][3] Peptide biohacking surges on social media, leveraging protein-derived signals for performance, while organic honey in biohacking diets eyes a 3 billion USD market by 2033.[2][8] Leaders respond innovatively: Jason Tebeau's Superhuman Protocol stacks pulsed electromagnetic fields, exercise with oxygen therapy, and red light for 15 to 20 minute sessions boosting ATP and circulation, backed by studies on microcirculation and mitochondrial recharge.[6] Compared to prior weeks, focus shifts from isolated supplements to stacked routines and cultural trends, with no verified price changes or supply issues. Overall, biohacking blends science and simplicity amid stable growth. (298 words) For great deals today, check out https://amzn.to/44ci4hQ
    Más Menos
    2 m
  • Biohacking Boom: How FDA Deregulation and GLP-1 Partnerships Are Reshaping Wellness Tech in 2026

    Biohacking Boom: How FDA Deregulation and GLP-1 Partnerships Are Reshaping Wellness Tech in 2026
    Apr 21 2026
    2 m
  • Peptide Therapy Boom 2026: The Biohacking Mainstream Moment Explained

    Peptide Therapy Boom 2026: The Biohacking Mainstream Moment Explained
    Apr 20 2026
    In the past 48 hours as of April 20, 2026, the biohacking industry shows surging momentum driven by peptide therapies and longevity trends, with no major market disruptions but clear signs of mainstream adoption.[2][5] Peptide therapy searches exploded year-over-year by 281 percent on Google, 459 percent on TikTok, and 412 percent on Instagram through early April, fueled by terms like NAD up 601 percent and GLP-1 up 177 percent, per Spate market research.[2] This builds on 2025s injectable peptide boom like BPC-157 and TB-500, now spilling into beauty with new topical products from brands echoing 2023s collagen wave.[2] Regulatory shifts are positive: the FDA is loosening rules on peptides amid GLP-1 democratization, with three oral pills including Wegovy released this month after years of shortages, boosting availability.[2] Emerging competitors include iCRYO, a cryotherapy biohacking franchise with over 100 units targeting suburbs for pain relief and IV add-ons, and chefless nutrition brands like Breadless serving GLP-1 users with supergreen meals.[3] Longevity retreats in Europe are going mainstream in 2026, shifting from elite clinics to science-backed programs for measurable health gains.[6] Ubiquinol innovations highlight mitochondrial healths rise, tied to biohacking culture and proactive aging narratives.[5] The wellness economy eyes 9.8 trillion dollars by 2029, with healthcare franchises growing 180 to 250 percent annually, up from prior years slower pace.[3] Consumer behavior tilts toward preventative biohacks, with leaders like Restore Hyper Wellness expanding low-entry franchises.[3] Compared to last weeks quieter reports, this periods social media spikes and peptide influx signal accelerated growth, though supply chains remain stable post-GLP-1 fixes.[2] Industry leaders respond by innovating access: Withings Body Scan 2 launches in the US, prompting global demand workarounds.[4] Overall, biohacking evolves from niche to scalable, with peptides and longevity leading a 33 percent predicted category surge.[2] (298 words) For great deals today, check out https://amzn.to/44ci4hQ
    Más Menos
    2 m
  • Biohacking Boom 2026: From Hype to Data-Driven Health Optimization

    Biohacking Boom 2026: From Hype to Data-Driven Health Optimization
    Apr 17 2026
    2 m